Complete Pathonecrosis and New Standards in HCC Management

[00:00:00]So, whether this is bridging or curative, I'm trying to achieve CPN now.

[00:00:04]We have great techniques now. Again, the rad seg method, other ablative methods, etc. Where we can get CPN. [music] And And my my job is to maximize that because I don't know the patient could have a problem. They could have developed comorbidities that that that prevent transplantation, etc. And I want to make sure that I've done the best job possible up front. And again, because we're able to give very effective therapies >> [music] >> without added toxicity has made my my job much easier. It's one thing if Oh man, I want to give my really high dose, but that means I'm going to have a lot of toxics. That that's not the case, right? Let me look at Look how how nice that that technique is is that Well, I can give you know, 400 gray, 500 gray, 600 gray and I'm not adding the toxicity. And so, I can bring that patient back to neil. I'm not going to say, "Oh gee, I'm going to He may decompensate based on what I'm doing."

[00:00:53]That's a really nice place to be. Let's go back 20 years, you know, the taste era, you know, the other embolizations.

[00:00:59]I mean, you know, there is a perception that if you do segmental taste, that patients do not decompensate. That's actually not true because you're giving them drug that has to be metabolized.

[00:01:08]And so, there is a drug metabolism phenomenon that still happens with taste that does not happen with Y90. You're just implanting something that sits there. And so, that's been a huge improvement over 25 years.